About Xpresys Lung
Xpresys Lung is a company based in Boulder (United States) founded in 2013 was acquired by Biodesix in July 2018. Xpresys Lung operates in a competitive market with competitors including Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
- Headquarter Boulder, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Xpresys Lung
Detailed funding history for Xpresys Lung
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Xpresys Lung
Xpresys Lung has secured backing from 1 investor. Prominent investors backing the company include Biodesix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Cancer detection diagnostics assays are developed and offered.
|
Locked | Locked | Locked |
Investor details for Xpresys Lung
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xpresys Lung
Investment portfolio details for Xpresys Lung
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xpresys Lung
Detailed financials for Xpresys Lung
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xpresys Lung Comparisons
Peer comparison for Xpresys Lung
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xpresys Lung
Xpresys Lung operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
Non-invasive molecular diagnostic tests for cancer are developed using epigenetics.
|
Detailed competitors of Xpresys Lung
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xpresys Lung
Complete news archive for Xpresys Lung
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xpresys Lung
Xpresys Lung was founded in 2013.
Xpresys Lung is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Provider of proteomics-based liquid biopsy test for lung cancer. The companys focus is on leveraging systems biology approaches and proteomic technologies to develop a diagnostic assay derived from a set of circulating protein biomarkers associated with lung cancer. The companys Xpresys Lung uses mass spectrometry to measure levels of a set of circulating proteins in addition to, but independent of other clinical factors such as age, smoking history, nodule size, and COPD diagnosis to diagnose lung cancer.
Xpresys Lung's top competitors include Guardant Health, GRAIL and BillionToOne.
Xpresys Lung has 1 investor. Key investors include Biodesix.